Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

Hatice Bolek; Omer Faruk Kuzu; Elif Sertesen Camoz; Saadet Sim; Serhat Sekmek; Hilal Karakas; Selver Isık; Murad Guliyev; Aysun Fatma Akkus; Deniz Tural; Cagatay Arslan; Sema Sezin Goksu; Ozlem Nuray Sever; Nuri Karadurmus; Cengiz Karacin; Mehmet Ali Nahit Sendur; Emre Yekedüz; Yuksel Urun

doi:10.1002/cac2.70003

Cancer Communications ›› 2025, Vol. 45 ›› Issue (5) : 572 -576. DOI: 10.1002/cac2.70003

LETTER TO THE JOURNAL

Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

Author information +

¹. Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey

². Ankara University Cancer Institute, Ankara, Turkey

³. Department of Medical Oncology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey

⁴. Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey

⁵. Department of Medical Oncology, Ege University School of Medicine, Izmir, Turkey

⁶. Department of Medical Oncology, Bilkent City Hospital, Ankara, Turkey

⁷. Department of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey

⁸. Department of Medical Oncology, Cerrahpasa School of Medicine, Istanbul, Turkey

⁹. Department of Medical Oncology, Trakya University School of Medicine, Edirne, Turkey

¹⁰. Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

¹¹. Medical Point Hospital, Izmir University of Economics, Izmir, Turkey

¹². Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey

¹³. Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey

¹⁴. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

yukselurun@gmail.com

Show less

History +

PDF

Cite this article

Download citation ▾

Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek, Hilal Karakas, Selver Isık, Murad Guliyev, Aysun Fatma Akkus, Deniz Tural, Cagatay Arslan, Sema Sezin Goksu, Ozlem Nuray Sever, Nuri Karadurmus, Cengiz Karacin, Mehmet Ali Nahit Sendur, Emre Yekedüz, Yuksel Urun. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium. Cancer Communications, 2025, 45(5): 572-576 DOI:10.1002/cac2.70003

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Cancer Stat Facts: Kidney and Renal Pelvis Cancer. [22 May 2024]. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html

[2]	Powles T, Burotto M, Escudier B, Apolo A, Bourlon M, Shah A, et al. Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO open. 2024; 9(5): 102994.

[3]	Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Journal of Clinical Oncology. 2024; 42(11): 1222–8.

[4]	Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. European Urology. 2023; 84(5): 449–54.

[5]	Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007; 356(2): 115–24.

[6]	Schmidt AL, Xie W, Gan CL, Wells C, Dudani S, Donskov F, et al. The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC). American Society of Clinical Oncology. 2021; 39(6 suppl): 339.

[7]	Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, et al. Sunitinib in patients with metastatic renal cell carcinoma: clinical outcome according to international metastatic renal cell carcinoma database consortium risk group. Clinical genitourinary cancer. 2018; 16(4): 298–304.

[8]	Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022; 128(11): 2085–97.

[9]	Bolek H, Yekedüz E, Ürün Y. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis. Cancer Treatment Reviews. 2023; 122: 102667.